FGEN
Price:
$9.07
Market Cap:
$27.12M
FibroGen, Inc. is a biopharmaceutical firm dedicated to discovering, developing, and bringing to market therapies that address significant medical conditions currently lacking effective treatments. Among its pipeline, FibroGen is advancing Roxadustat, an orally administered small molecule that inhibits hypoxia inducible factor prolyl hydroxylases. This drug has successfully completed Phase III clinical trials in the US, Europe, China, and Japan for treating anemia in chronic kidney disease, and is currently in Phase II/III development in China for anemia linked to myelodysplastic syndromes. Additionally, the company is progressing Pamrevlumab, a human monoclonal antibody designed to block co...[Read more]
Industry
Biotechnology
IPO Date
2014-11-14
Stock Exchange
NASDAQ
Ticker
FGEN
According to FibroGen, Inc.’s latest financial reports and current stock price. The company's current ROE is -234.28%. This represents a change of -6765.29% compared to the average of 3.51% of the last 4 quarters.
The mean historical ROE of FibroGen, Inc. over the last ten years is 64.14%. The current -234.28% ROE has changed -465.26% with respect to the historical average. Over the past ten years (40 quarters), FGEN's ROE was at its highest in in the December 2025 quarter at 847.89%. The ROE was at its lowest in in the September 2025 quarter at -871.93%.
Average
64.14%
Median
-19.69%
Minimum
-610.73%
Maximum
1.37%
Discovering the peaks and valleys of FibroGen, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 209.28%
Maximum Annual ROE = 1.37%
Minimum Annual Increase = -2995.87%
Minimum Annual ROE = -610.73%
| Year | ROE | Change |
|---|---|---|
| 2025 | -610.73% | -2995.87% |
| 2024 | 21.09% | -84.85% |
| 2023 | 139.22% | -89.83% |
| 2022 | 1.37% | -1087.38% |
| 2021 | -138.67% | 209.28% |
| 2020 | -44.84% | 200.66% |
| 2019 | -14.91% | -12.13% |
| 2018 | -16.97% | -24.26% |
| 2017 | -22.41% | -43.38% |
| 2016 | -39.58% | -18.07% |
The current ROE of FibroGen, Inc. (FGEN) is greater than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
-150.14%
5-year avg
156.02%
10-year avg
64.14%
FibroGen, Inc.’s ROE is greater than Kezar Life Sciences, Inc. (-58.35%), greater than Tempest Therapeutics, Inc. (-729.89%), greater than Aligos Therapeutics, Inc. (-139.47%), greater than OnKure Therapeutics, Inc. (-61.02%), less than Mersana Therapeutics, Inc. (183.15%), greater than X4 Pharmaceuticals, Inc. (-94.90%), greater than PDS Biotechnology Corporation (-346.03%), less than Celularity Inc. (411.46%), greater than Xilio Therapeutics, Inc. (-117.24%), greater than Actinium Pharmaceuticals, Inc. (-218.67%),
| Company | ROE | Market cap |
|---|---|---|
| -58.35% | $53.86M | |
| -729.89% | $5.46M | |
| -139.47% | $32.67M | |
| -61.02% | $61.26M | |
| 183.15% | $145.36M | |
| -94.90% | $398.03M | |
| -346.03% | $53.30M | |
| 411.46% | $18.10M | |
| -117.24% | $57.80M | |
| -218.67% | $32.32M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like FibroGen, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like FibroGen, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is FibroGen, Inc.'s ROE?
How is the ROE calculated for FibroGen, Inc. (FGEN)?
What is the highest ROE for FibroGen, Inc. (FGEN)?
What is the 3-year average ROE for FibroGen, Inc. (FGEN)?
What is the 5-year average ROE for FibroGen, Inc. (FGEN)?
How does the current ROE for FibroGen, Inc. (FGEN) compare to its historical average?